Patents by Inventor Jay Sarup

Jay Sarup has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Catalytic domains of the human hepatocyte growth factor receptor tyrosine kinase, and materials and methods for identification of inhibitors thereof
    Publication number: 20040009568
    Abstract: The identification, isolation, purification, and characterization of the catalytic domain of the human hepatocyte growth factor receptor kinase (hHGFR) are described. A crystal structure of the hHGFR kinase domain is reported herein. This structure provides a three-dimensional description of the binding site of the hHGFR for structure-based design of small molecule inhibitors thereof as therapeutic agents. The kinase domain of human HGFR and its associated crystal structure is described for use in the discovery, identification and characeterization of modulators of human HGFR.
    Type: Application
    Filed: March 25, 2002
    Publication date: January 15, 2004
    Inventors: Barbara Mroczkowski, Michael Hickey, Michele Ann McTigue, Brion William Murray, Hans Parge, Jay Sarup, Jeff Zhu
  • Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof
    Patent number: 6670167
    Abstract: The present invention relates to the identification, isolation and purification of the catalytic domain of the human effector checkpoint protein kinase (hChk1). A 1.7Å crystal structure of the hChk1 kinase domain in the active conformation is reported herein. The kinase domain of hChk1 and its associated crystal structure is described for use in the discovery, identification and characterization of inhibitors of hChk1. This structure provides a three-dimensional description of the binding site of the hChk1 for structure-based design of small molecule inhibitors thereof as therapeutic agents. Inhibitors of hChk1 find utility in the treatment of hyperproliferative disorders such as HIV and cancer.
    Type: Grant
    Filed: December 14, 1999
    Date of Patent: December 30, 2003
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Ping Chen, Mark Anderson, Ya-Li Deng, Smita Gaur, Chen Chen Kan, Chun Luo, Karen Lundgren, Stephen Margosiak, Binh Nguyen, Patrick O'Connor, James Register, Anna Tempczyk Russell, Jay Sarup
  • Catalytic domain of the human effector cell cycle checkpoint protein kinase Chk1 materials and methods for identification of inhibitors thereof
    Publication number: 20030235899
    Abstract: The present invention relates to the identification, isolation and purification of the catalytic domain of the human effector checkpoint protein kinase (hChk1). A 1.7 Å crystal structure of the hChk1 kinase domain in the active conformation is reported herein. The kinase domain of hChk1 and its associated crystal structure is described for use in the discovery, identification and characterization of inhibitors of hChk1. This structure provides a three-dimensional description of the binding site of the hChk1 for structure-based design of small molecule inhibitors thereof as therapeutic agents. Inhibitors of hChk1 find utility in the treatment of hyperproliferative disorders such as HIV and cancer.
    Type: Application
    Filed: January 28, 2003
    Publication date: December 25, 2003
    Inventors: Ping Chen, Mark Anderson, Ya-Li Deng, Smita Gaur, Chen Chen Kan, Chun Luo, Karen Lundgren, Stephen Margosiak, Binh Nguyen, Patrick O'Connor, James Reqister, Anna Tempczyk Russell, Jay Sarup